Harel Insurance Investments & Financial Services Ltd. decreased its stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 19.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 373,982 shares of the company's stock after selling 89,285 shares during the quarter. Harel Insurance Investments & Financial Services Ltd. owned about 0.81% of Urogen Pharma worth $4,136,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in shares of Urogen Pharma during the fourth quarter worth $59,000. Lazard Asset Management LLC purchased a new stake in Urogen Pharma during the fourth quarter valued at $67,000. GAMMA Investing LLC raised its stake in Urogen Pharma by 6,908.4% during the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after purchasing an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in Urogen Pharma during the fourth quarter valued at $101,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in Urogen Pharma during the fourth quarter valued at $126,000. Institutional investors own 91.29% of the company's stock.
Insider Transactions at Urogen Pharma
In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the sale, the insider directly owned 153,378 shares in the company, valued at $1,130,395.86. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is currently owned by insiders.
Urogen Pharma Stock Performance
NASDAQ URGN traded down $0.09 during trading on Monday, hitting $13.49. The stock had a trading volume of 745,759 shares, compared to its average volume of 1,080,641. The stock has a market capitalization of $622.02 million, a price-to-earnings ratio of -4.24 and a beta of 1.02. Urogen Pharma has a one year low of $3.42 and a one year high of $18.15. The stock has a 50 day simple moving average of $9.67 and a 200 day simple moving average of $10.24.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. On average, sell-side analysts predict that Urogen Pharma will post -3.12 EPS for the current year.
Analysts Set New Price Targets
A number of research firms recently issued reports on URGN. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. HC Wainwright raised shares of Urogen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price target on the stock in a research note on Monday, June 16th. Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the company a "buy" rating in a research note on Friday, June 13th. The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the company a "neutral" rating in a research note on Friday, June 13th. Finally, Guggenheim reaffirmed a "buy" rating and set a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $32.86.
Read Our Latest Stock Report on Urogen Pharma
Urogen Pharma Company Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Articles
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
